| Identification | Back Directory | [Name]
Acetamide, N-[4-[7-cyano-4-(4-morpholinylmethyl)-2-quinolinyl]phenyl]- | [CAS]
2143072-85-7 | [Synonyms]
Acetamide, N-[4-[7-cyano-4-(4-morpholinylmethyl)-2-quinolinyl]phenyl]- | [Molecular Formula]
C23H22N4O2 | [MOL File]
2143072-85-7.mol | [Molecular Weight]
386.45 |
| Chemical Properties | Back Directory | [Boiling point ]
642.7±55.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [solubility ]
DMSO:38.65(Max Conc. mg/mL);100.0(Max Conc. mM) | [form ]
Solid | [pka]
14.58±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
RAGE 229 is an antagonist of the interaction between the cytoplasmic tail of the receptor for advanced glycation end products (ctRAGE) and the formin, Diaphanous-1 (DIAPH1) (KD for binding to ctRAGE = 2 nM). RAGE 229 inhibits the migration of human aortic smooth muscle cells in an in vitro wound healing assay (IC50 = 120 nM). RAGE 229 reduces short- and long-term complications of diabetes in mouse models, without lowering blood glucose concentrations. RAGE 229 also reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 and attenuates inflammatory signaling in diabetic mice. | [storage]
Store at -20°C |
|
|